
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen is well-positioned for growth and success due to its strong financials, strategic focus on a targeted market of rheumatologists, and continued expansion of its product portfolio. With a projected revenue growth of 5-10% Y/Y and plans for a new test launch every year, Exagen's positive outlook is further cemented by its development in lupus nephritis testing and biopharma services, strong sales rep traction, and emphasis on becoming a value-added partner to rheumatologists. Its current financials, including its low multiple of 1.3x projected 2026 revenue and its goal of achieving positive adjusted EBITDA in Q4'27, make it a promising investment opportunity.
Bears say
Exagen is experiencing headwinds in its average selling price (ASP) and gross margins, leading to a decline in their adjusted EBITDA. Additionally, their projected revenue and cash flow breakeven have been pushed back, raising concerns about their long-term financial sustainability. The company also faces stiff competition from established players in the medical testing industry, which may threaten their market share and growth potential.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares